Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Channel of Togo.
Press releases published on May 29, 2025

Erasca to Present at Upcoming Investor Conferences in June
SAN DIEGO, May 29, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today …

Immuneering to Present at the Jefferies Global Healthcare Conference
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced that …

Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
Topline data expected by year end Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA, May 29, 2025 (GLOBE …

MDaudit and Streamline Health Announce Definitive Merger Agreement
The combined entity supports healthcare organizations nationwide with an aggregate Net Patient Revenue of more than $300B and brings together best-in-class billing compliance and revenue integrity solutions to empower health systems with actionable …

Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day
Teva outlines acceleration path into a leading biopharma company Innovative medicines franchise on track to exceed $5 billion by 2030, led by AUSTEDO® (deutetrabenazine), AJOVY® (fremanezumab), UZEDY® (risperidone) and late-stage pipeline with blockbuster …

Aligos Therapeutics to Present at the Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today …

Prime Medicine to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will …

Avadel Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
DUBLIN, Ireland, May 29, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at …

Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
THE WOODLANDS, Texas, May 29, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference, taking place in New York …

Beghou Consulting Adds New Partners to Strengthen Market Access, Cell & Gene Therapy, and Technology Capabilities
EVANSTON, Ill., May 29, 2025 (GLOBE NEWSWIRE) -- Beghou Consulting, a leading provider of data, analytics, and technology solutions for life sciences commercialization, today announced that highly-regarded industry leaders Robert Rouse and Jason Stephani …

SweetWater Brewing and Zoo Atlanta Celebrate 18 Years of Collaboration with a Special Edition Beer
ATLANTA, May 29, 2025 (GLOBE NEWSWIRE) -- SweetWater Brewing Company (“SweetWater Brewing” or “SweetWater”), the largest craft brewer in the Southeast and a Tilray Brands, Inc. company (NASDAQ: TLRY and TSX: TLRY) is thrilled to extend their partnership …

Safety Shot Reminds Shareholders to Vote Their Proxy at the Upcoming Annual Shareholder Meeting
SCOTTSDALE, Ariz., May 29, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (“SHOT”, "Safety Shot”, or the “Company”), a wellness and dietary supplement company, reminds shareholders that its Annual Shareholders’ Meeting will be held on Thursday, …

Digital Landia, LLC, in Cooperation with PetVivo Holdings, Inc., Announces Invite-Only MVP Availability Amid Stress-Testing & Debugging Phase
MIAMI, FL, May 29, 2025 (GLOBE NEWSWIRE) -- Digital Landia, LLC (“Digital Landia”), owner of Agentic.Pet, an autonomous pet artificial intelligence ecosystem, in cooperation with PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW) and its wholly owned …

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the completion of patient …

Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer
PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced the appointment …

Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, metabolic and cardiovascular diseases, …

Vima Therapeutics Launches to Advance the First Oral Therapy for People with Dystonia and Related Movement Disorders
- $60 million Series A led by Atlas Venture, and founded by an expert team of physicians and scientists - VIM0423, a potential first-in-class oral medicine for isolated dystonia, is currently being studied in a Phase 1 clinical trial; Phase 2 planned for …

Crescent Biopharma to Present at the Jefferies Global Healthcare Conference
WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent”), a private biotechnology company developing novel precision-engineered molecules targeting validated biology to advance care for patients with solid tumors, today …

Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference
SAN FRANCISCO and BOSTON, May 29, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at …

Incannex Healthcare Inc. Advances IHL-42X RePOSA Trial to Phase 3 Following FDA Protocol Clearance
NEW YORK and MELBOURNE, Australia, May 29, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage pharmaceutical company developing novel combination therapies, today announced that the Phase 3 component of the RePOSA clinical …